Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow SPRUCE BIOSCIENCES, INC.

Get SEC filing alerts via email and in your feed for SPRUCE BIOSCIENCES, INC.

SPRB

SPRUCE BIOSCIENCES, INC.

About SPRUCE BIOSCIENCES, INC.

Spruce Biosciences is a biopharmaceutical company developing therapies for neurological and rare diseases, including enzyme replacement and small molecule drugs. Its pipeline features treatments for MPS IIIB, depression, and congenital adrenal hyperplasia. The company focuses on targeted, biologic and small molecule therapeutics, leveraging strategic licensing, collaborations, and proprietary IP to address high unmet medical needs in niche markets worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from SPRUCE BIOSCIENCES, INC.

1
1
SPRUCE BIOSCIENCES, INC. Spruce Biosciences Reports $12.3 Million Net Loss in Q1 2026, Focuses on TA-ERT Development

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
SPRUCE BIOSCIENCES, INC. Spruce Biosciences Reports $39 Million Net Loss Amid Clinical Development Progress

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
SPRUCE BIOSCIENCES, INC. Spruce Biosciences Reports No Revenue and Significant Losses in Latest Financial Filing

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
SPRUCE BIOSCIENCES, INC. Spruce Biosciences Reports No Revenue and Significant Losses in Latest Financial Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
SPRUCE BIOSCIENCES, INC. Spruce Biosciences Reports $14M Net Loss in Q1 2025, Faces Financial Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
SPRUCE BIOSCIENCES, INC. Spruce Biosciences Reports Increased Net Loss and Decreased Collaboration Revenue for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
SPRUCE BIOSCIENCES, INC. Spruce Biosciences Reports Financial Results, Implements Cost Reduction Measures, and Explores Additional Financing Options

Via official filing (AI summary) | over 1 year ago | 0 comments